

Gabriel Rinnerthaler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1167181/publications.pdf>

Version: 2024-02-01

54
papers

940
citations

516710

16
h-index

477307

29
g-index

55
all docs

55
docs citations

55
times ranked

1726
citing authors

#	ARTICLE	IF	CITATIONS
1	Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer – Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT). <i>Breast Care</i> , 2022, 17, 1-9.	1.4	3
2	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	7.0	17
3	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 63-72.	1.9	1
4	Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. <i>BMC Cancer</i> , 2022, 22, 51.	2.6	3
5	Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry. <i>Cancer Research</i> , 2022, 82, P1-16-03-P1-16-03.	0.9	0
6	Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry. <i>Cancer Research</i> , 2022, 82, P1-21-08-P1-21-08.	0.9	1
7	Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib. <i>Cancer Research</i> , 2022, 82, P2-13-30-P2-13-30.	0.9	0
8	Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy – A Retrospective Bi-Centric Cohort Study. <i>Cancers</i> , 2022, 14, 93.	3.7	7
9	Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 507-507.	1.6	15
10	Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry. , 2021, , .		0
11	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. <i>Cancers</i> , 2021, 13, 650.	3.7	4
12	Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. <i>Future Science OA</i> , 2021, 7, FSO644.	1.9	2
13	Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg – a report from the AGMT COVID-19 Registry. <i>GeroScience</i> , 2021, 43, 1877-1897.	4.6	3
14	Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4981.	4.1	33
15	Top 3 Abstracts concerning hormone-receptor-positive early breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 252-256.	0.5	1
16	Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1131-1136.	1.9	4
17	Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition. <i>Lung Cancer</i> , 2021, 159, 84-95.	2.0	12
18	Expert Discussion: Immunotherapy in Breast Cancer – Ready for Prime Time?. <i>Breast Care</i> , 2021, 16, 188-191.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer. <i>Breast Care</i> , 2021, 16, 664-676.	1.4	1
20	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 17588359211042301.	3.2	1
21	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110423.	3.2	3
22	Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. <i>Breast Cancer Research</i> , 2021, 23, 112.	5.0	75
23	Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. <i>Cancers</i> , 2020, 12, 2812.	3.7	3
24	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2775.	2.4	10
25	<p>Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10615-10629.	1.9	11
26	Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy. <i>Medicine (United States)</i> , 2020, 99, e20149.	1.0	4
27	Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1663.	2.4	7
28	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	4.1	31
29	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. <i>Journal of Clinical Medicine</i> , 2019, 8, 1014.	2.4	41
30	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 707-717.	3.6	15
31	MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. <i>Breast Cancer Research</i> , 2019, 21, 20.	5.0	52
32	Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). <i>Breast Cancer Research</i> , 2019, 21, 19.	5.0	44
33	Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 159-166.e3.	2.3	14
34	HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1115.	4.1	144
35	Nonmetastatic pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 627-637.	2.0	4
36	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. <i>Nature Communications</i> , 2018, 9, 1219.	12.8	20

#	ARTICLE	IF	CITATIONS
37	Clonal evolution and heterogeneity in metastatic head and neck cancer – An analysis of the Austrian Study Group of Medical Tumour Therapy study group. <i>European Journal of Cancer</i> , 2018, 93, 69-78.	2.8	25
38	Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial. <i>Cancer Medicine</i> , 2018, 7, 5962-5972.	2.8	23
39	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). <i>BMC Cancer</i> , 2018, 18, 1074.	2.6	12
40	ASCO 2018 highlights: metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 276-279.	0.5	14
41	SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 208-212.	0.5	5
42	Cure in metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 172-179.	0.5	23
43	DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer. <i>Theranostics</i> , 2018, 8, 2278-2288.	10.0	28
44	Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16512-16520.	1.8	71
45	SABCS 2016: systemic therapy for metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 86-89.	0.5	8
46	ASCO 2017 – making a difference in cancer care with you. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 187-189.	0.5	0
47	miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites. <i>International Journal of Molecular Sciences</i> , 2016, 17, 156.	4.1	71
48	Adjuvant medical treatment for breast cancer in elderly and old women. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 17-19.	0.5	5
49	CDK4/6 inhibition in luminal breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 76-81.	0.5	8
50	Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. <i>Oncotarget</i> , 2016, 7, 51494-51502.	1.8	35
51	Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Efficacy results of a phase II trial (AGMT MBC-6). <i>Journal of Clinical Oncology</i> , 2016, 34, 1032-1032.	1.6	0
52	Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. <i>Anticancer Research</i> , 2015, 35, 517-21.	1.1	11
53	Bone-Targeted Therapy in Metastatic Breast Cancer - All Well-Established Knowledge?. <i>Breast Care</i> , 2014, 9, 323-330.	1.4	13
54	Multi-gene signatures in breast cancer: actual clinical impact. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 16-21.	0.5	1